



96-Well Caco**Ready** User's Manual

LIMITED SINGLE-USE LICENSE

This is a binding legal agreement (this "License") between you (the "Customer" or "You"), and MedTech Barcelona regarding the enclosed "CacoReady™" System (this "Product"). Carefully read this License before opening the sealed package. BY OPENING THE SEALED PACKAGE, YOU AGREE TO BE BOUND BY THE TERMS OF THIS LICENSE. If You do not agree to the terms of this License, and You have not opened the sealed package, promptly notify MedTech Barcelona in writing and return the unopened Product and all accompanying items (including all written material and containers) to MedTech Barcelona within five (5) business days.

This License sets forth the Customer's rights to use this Product. The meaning of "Product" hereunder shall include any parts thereof and any documentation made available for use with this Product. Upon receipt of the applicable fee, MedTech Barcelona grants to the Customer the personal, non-exclusive, and non-transferable right to use this Product worldwide. The Customer is solely responsible for the use of this Product by any person.

The Customer acknowledges and agrees that the manufacture, use, sale, or import of this Product may be subject to one or more issued or pending patent applications and the corresponding foreign equivalents owned or controlled by MedTech Barcelona. The Customer acknowledges and agrees that the documentation and components included in the Product are the proprietary and copyrighted material of MedTech Barcelona. The purchase and use of this Product shall be governed under MedTech Barcelona's standard Terms and Conditions, and any other written agreement between the parties, and such terms and agreements are incorporated herein by reference. Your purchase of this Product, subject to this License, conveys to the Customer the non-transferable right to use the purchased amount of the Product and components of the Product in this shipment in research conducted by the Customer; such right shall expire upon completion of the experiments stemming from this shipment.

The Customer shall not detach living cells from the Product and shall not amplify genetic material (DNA, RNA) for purposes other than quantitative or qualitative analysis of proteins or nucleotide sequences.

The Customer shall not sell or otherwise transfer (a) this Product, (b) any components of this Product, or (c) any materials made using this Product or its components. Also, the Customer shall not use this Product or its components for Commercial Purposes other than those defined herein, and especially will not be able to: (1) make use of this Product in manufacturing; (2) make use of this Product for therapeutic, diagnostic or prophylactic purposes; or (3) resale this Product, whether or not such Product is resold for research purposes. For clarification, the Customer may use and transfer information or materials made through the use of this Product to support the Customer's research in any manner the Customer deems necessary or appropriate, and the Customer may provide services to third parties.

If you have any questions or need information on obtaining a license to use this Product or any of its components for purposes beyond the scope of this License, please contact MedTech Barcelona at:

reagents@medtechbcn.com

Table of contents

| | |
|--|----|
| <i>PRODUCT DESCRIPTION</i> | 4 |
| <i>INTENDED USE</i> | 4 |
| <i>PRINCIPLE</i> | 4 |
| <i>TIMELINE FOR DELIVERY AND EXPERIMENTAL PROCEDURES</i> | 5 |
| <i>EQUIPMENT (NOT INCLUDED)</i> | 6 |
| <i>CONSUMABLES</i> | 6 |
| <i>SOLUTIONS (MAY BE INCLUDED)</i> | 6 |
| <i>HANDLING</i> | 7 |
| Replacement of Shipping Medium | 7 |
| <i>QUALITY CONTROL OF THE BARRIER SYSTEM</i> | 8 |
| Pre-assay Quality control – TEER Measurement | 8 |
| Post-assay Quality Control – Lucifer Yellow (LY) Paracellular Permeability Assay | 9 |
| <i>GENERAL PROTOCOL FOR TRANSPORT ASSAYS</i> | 10 |
| General Considerations | 10 |
| Recommended Reference Compounds | 10 |
| Sample Plate Layout | 10 |
| Protocol | 11 |
| <i>EVALUATION OF COMPOUND PERMEABILITY</i> | 13 |
| Apparent Permeability Coefficient (P_{app}) | 13 |
| Efflux Ratio (ER) | 13 |
| Mass Balance | 13 |
| Data for Reference Compounds | 14 |
| <i>REFERENCES</i> | 14 |

Product Description

CacoReady is an *in vitro* cell-based model built on polarized human colorectal adenocarcinoma-derived cells (Caco-2) which resemble the intestinal epithelial barrier. Cells differentiate for 21-days in 96 Transwell® inserts with semi-porous (1 µm) polystyrene (PET) membrane (CORNING Cat#3392) resulting in an apical compartment and a basal compartment that mimic the intestinal lumen and the blood circulation, respectively.

Caco-2 cells are considered a reference cellular model for assessing drug passive diffusion and/or active transport and can easily be adapted for high-throughput screening of compounds¹.

CacoReady is delivered in a 96-well/plate format with a unique Shipping Medium (a gel-like cell culture medium) established by MEDTECH BARCELONA which enables the transport of cells at room temperature and in a ready-to-use format.

Intended Use

This product is mainly indicated for *in vitro* evaluation of:

- drug permeability by passive diffusion and/or active transport through a physiologically relevant barrier
- carrier-mediated transport mechanisms
- drug toxicity

NOTE: This cell-based model is intended for scientific research purposes only. Not for human or veterinary use.

Principle

Passive permeability and outward active transport of drugs are carried out with Caco-2 cells that endogenously express relevant human drug transporters in the apical domain of the plasma membrane. In the experimental setup, these cells will be differentiated on Transwell® inserts to form a tight cell monolayer that prevents media from wicking between the insert (apical compartment) and the plate well (basal compartment). Efflux transporters localized in the apical side will introduce a basolateral-to-apical bias in the distribution of substrate compounds between the two compartments.

In a standard assay design, the reaction is initiated by filling either compartment with the solution containing the test compound. The distribution is assessed over time by withdrawing and analyzing samples from both compartments. After normalization, the speed of translocation is obtained for both directions. The ratio of the two values is a measure of the passive and active transport mechanisms involved in the distribution of the compound.

Handling and experimental procedures are provided below. The manual has been written for users with experience in cell culturing and pharmacological drug discovery *in vitro* testing experiments. For more detailed advice and training opportunities, please contact us at reagents@medtechbcn.com.

Timeline for Delivery and Experimental Procedures

- Day 1: Start of Production (Seeding of cells)
- Day 14: Pre-shipping Quality Control (TEER and Lucifer Yellow)
- Days 14–15: Package Dispatch (depending on destination)
- Days 16–17: Package Delivery
- Day 18: Replacement of Shipping Medium (liquefaction)
- Day 21–25: Quality Control Experiments and Medium Replacement/Assay Performance (see Table 1)

Packages are dispatched on Mondays/Tuesdays and delivered within 24–48 h to EU countries, 48–72 h to USA, and 48–96 h to Asian countries. For other locations and customized schedules, please contact us at reagents@medtechbcn.com.

The recommended timing overview for permeability assays is Day 21 (Monday) (see Figure 1 for details).

| CacoReady | Monday | Tuesday | Wednesday | Thursday | Friday |
|---------------|---------------------------------------|---------------------|------------------------------|----------|------------------------|
| Week 0 | 12:00 p.m. (CET) last ordering day | | | | |
| Week 1 | Pre-Production | | Start of Production Day 1 | | |
| Week 2 | Day 7 | | | | |
| Week 3 | Shipment Day 14 | Reception of Plates | | | Liquefaction Day 18 |
| Week 4 | Perform Assay | | | | Day 25 |
| | Day 21 | | | | |

Figure 1. Timeline of manufacturing and operation for CacoReady in 24-well format.

In case you choose to conduct the experiments later, TEER measurements and medium replacement must be carried out as follows:

| DAY OF EXPERIMENT | TEER MEASUREMENT | MEDIUM REPLACEMENT |
|--------------------|--|---------------------------------------|
| Tuesday (Day 22) | Monday (Day 21) | Monday (Day 21) |
| Wednesday (Day 23) | Monday (Day 21) Wednesday (Day 23) | Monday (Day 21) |
| Thursday (Day 24) | Monday (Day 21) Wednesday (Day 23) | Monday (Day 21) Wednesday (Day 23) |
| Friday (25) | Monday (Day 21) Wednesday (Day 23) Friday (25) | Monday (Day 21) Wednesday (Day 23) |

Table 1. Recommended day for TEER measurement and medium replacement.

NOTE: These steps enable the planning of the assay according to the user's convenience.

IMPORTANT NOTE: TEER evaluation will be carried out on Monday (Day 21) before performing any further processing, including medium replacement. Based on our experience with long-distance shipments and/or extreme temperatures at destination, in case TEER values are low, it is recommended to perform a medium change and wait until Wednesday to let the cells recover. On Wednesday, read the TEER again and perform the assay accordingly.

Equipment (not included)

- Cell culture laminar flow hood
- CO₂ incubator
- Water bath
- Multichannel pipettes
- Automatic multichannel micropipette (recommended)
- Aspiration system
- 96-well format vacuum manifold (Drummond Cat# 3-000-093 recommended)
- Trans-Epithelial Electrical Resistance (TEER) meter (WPI EVOM series)
- 96-well electrode (WPI EVM-EL-03-03-05 recommended)
- Fluorometer (Fluoroskan Ascent CF)
- Quantitative analytics equipment

NOTE: An electrode adaptor may be required depending on the model of the TEER meter you are using. Please refer to WPI for concerns regarding compatibility.

Consumables

- Reservoir plate (provided by MedTech Barcelona)
- Sterile culture medium containers (i.e., Costar 50 ml, Cat# 4870) (*not provided*)
- 15 and 50 mL conical tubes and 1.5 mL Eppendorf tubes (*not provided*)
- Pipette tips (*not provided*)

Solutions (may be included)

NOTE: MedTech Barcelona can supply Medium and Transport Buffer if required.

- Caco-2 Cell Culture Medium: Dulbecco's Modified Eagle's Medium – low glucose (1 g/L) (SIGMA Cat# D5546) supplemented with (final concentrations):
 - 10 % V/V Fetal Bovine Serum (BIOWEST Cat# DE14-801F)
 - 2 mM L-glutamine (LONZA Cat# BE17-605F)
 - 100 U/mL; 0.1 mg/mL Penicillin-Streptomycin (LONZA Cat# DE17-602F)
- Transport Buffer solution: Hank's 1X Balanced Salt Solutions (HBSS 1x) (HyClone Cat# SH30268)
- Post-assay quality control: Lucifer Yellow (LY) (SIGMA L0259)

- Recommended reporter for Low Permeability Substrates: Atenolol (SIGMA Cat#A7655)
- Recommended reporter for High Permeability Substrates: Metoprolol (SIGMA Cat#M5391)
- Recommended reporter for MDR1 (Pgp) Substrates: Digoxin (SIGMA Cat# 04599)
- Recommended reporter for MDR1 (Pgp) Inhibitors: Verapamil (SIGMA Cat# V4629)
- Recommended reporter for BCRP Substrates: Prazosin (SIGMA Cat# P7791)
- Recommended reporter for BCRP Inhibitors: Ko143 (SIGMA Cat# K2144)

NOTE: If the specified reagents are not available, other reagents with similar features and specifications can be used.

Handling

Upon reception, retrieve the zipped bags containing the plates. Open the zip and leave the bag in a dark location at room temperature until Day 18 (refer to Timeline; Figure 1).

Replacement of Shipping Medium

CAUTION: Never handle more than one plate at a time while changing the shipping medium. Re-solidification of the shipping medium may damage the cell monolayer.

These steps will be carried out on Day 18 (refer to Timeline; Figure 1). Perform all manipulation under sterile conditions.

1. Retrieve the plates from the bags and remove the parafilm wrap.
2. Incubate the plates in a 5 % CO₂ humidified atmosphere at 37 °C for 4 hours, until the shipping medium reaches liquefaction.
3. Remove one CacoReady plate from the incubator and place it inside the laminar flow hood, along with one reservoir plate.
4. Using sterile procedures (inside the laminar flow hood), fill a sterile reagent reservoir with 50 mL of pre-warmed (37 °C) Caco-2 cell culture medium.
5. Open the CacoReady plate and the reservoir plate, and leave their lids upwards, next to the plates.
6. Carefully lift the 96-integrated apical compartments of the CacoReady plates and transfer them onto the reservoir plate.
7. Remove all liquefied shipping medium from the basal compartments of the CacoReady plate via aspiration with the 96-well manifold.
8. Using a multichannel pipette, dispense 250 µL of Caco2- cell culture medium from the sterile reservoir, and fill, the basal compartments of the CacoReady plate, column by column.
9. Using the aspiration manifold connected to a vacuum pump (adjust aspiration flux to medium-low), aspirate the liquefied shipping medium from the apical integrated inserts of the CacoReady plate, taking care not to disrupt the monolayer. Make sure the shipping medium has been removed from all wells. Approximately 10 µL of medium will be left in each well.
10. Using a multichannel pipette, dispense 75 µL of Caco-2 cell culture medium from the sterile reservoir, and fill, the apical compartments of the CacoReady plate, column by column. Always add the medium against the wall of the well, and not directly onto the cell monolayers.
11. Carefully return the apical inserts onto the basal compartment of the CacoReady plate. Replace the lid and place it inside the cell culture incubator, set at 37 °C and 5 % CO₂.

12. Once the shipping medium has been substituted by fresh Caco-2 cell culture medium, the plates should be placed inside the incubator until next Monday (Day 21). Replacement with a new fresh medium will be carried out once (Day 21) or twice (Days 21 and 23) depending on the day of the assay (refer to Table 1 for details), following the procedure described above.

NOTE: Do not discard the reservoir plate, as it will be used in the permeability assay.

Quality Control of the Barrier System

Pre-assay Quality control – TEER Measurement

This section provides general instructions for TEER evaluation. It is important to carefully read the instructions of the TEER measurement equipment in conjunction with these instructions.

The timeline for TEER evaluation is detailed in Table 1. TEER measurement will be carried out before performing any further processing, including the experiment and the medium replacement.

NOTE: Never perform the TEER measurement with the shipping medium. Do not repeat TEER measurements in the same well.

For TEER evaluation, follow the steps below:

1. Sterilize the electrode (probe) by submerging both tips in 70 % ethanol for 5 minutes.
2. Equilibrate the electrode (probe) for 5 minutes in Caco-2 cell culture medium, pre-warmed at room temperature.
3. While the electrode is equilibrating, remove the CacoReady plate from the incubator and place it in a laminar flow hood. Allow the plate to reach room temperature (approximately 20 minutes), as TEER measurements should be performed under this condition.

NOTE: It is highly recommended to use the WPI STX 100C96 electrode to prevent cell damage. Watch out to set the electrode in the right position.

4. Place the electrode onto the well and record the resistance readout in ohms (Ω) for each well. TEER value is the result of multiplying the resistance value by the cell growth area (cm^2).

Acceptance Criterion

| | |
|--|-----------------------------------|
| Active membrane surface (Corning plates) | 0.14 cm^2 |
| TEER value | > 500 $\Omega \times \text{cm}^2$ |


Post-assay Quality Control – Lucifer Yellow (LY) Paracellular Permeability Assay

Prepare a 1 mg/mL (2.187 mM) LY solution in sterile ddH₂O. Make aliquots (e.g., 500 µL) and store them at -20 °C.

Dilute LY stock solution in transport assay buffer to a 100 µM final concentration. Working dilution will be used to prepare the calibration curve and for the LY test (see Figure 2 for details).

To proceed with the LY permeability assay, follow the steps below:

1. Prewarm the 100 µM working LY solution at 37 °C covered with foil to protect it from light.
2. Prepare the calibration curve by making serial 1:2 dilutions of the working solution (see Figure 2).
3. Rinse both the apical and the basal compartments gently with transport assay buffer following the procedure described in “Replacement of Shipping Medium” (steps 4–11).
4. Remove the transport assay buffer from the apical and basal compartments following the same procedure.
5. Add 75 µL of 100 µM LY working dilution into the apical compartment.
6. Add 250 µL of transport assay buffer to the basal compartment.
7. Incubate the CacoReady plate, protected from light, in the cell incubator (at 37 °C and 5 % CO₂) for 1 h.
8. Take 200 µL from the basal compartment and from the calibration curve, and load them into an empty 96-well plate for fluorescence-based assays. Mix well and avoid bubble formation when getting samples and standards!
9. Read the fluorescence intensity in a fluorometer at 485/527 excitation/emission wavelengths.



| | | | | | | | | | | | | |
|---------------|----------|----------|----------|----------|----------|----------|----------|---------|---------|-------|-------|--------|
| 0 µM BLANK | 0.048 µM | 0.097 µM | 0.195 µM | 0.390 µM | 0.781 µM | 1.562 µM | 3.125 µM | 6.25 µM | 12.5 µM | 25 µM | 50 µM | 100 µM |
|---------------|----------|----------|----------|----------|----------|----------|----------|---------|---------|-------|-------|--------|

Figure 2. General procedure for LY permeability assay and recommended concentrations for the calibration curve.

Acceptance Criterion

| | |
|--|-----------------------------|
| LY Paracellular Flux | ≤ 0.7 % |
| LY apparent permeability (P _{app}) | ≤ 1 x 10 ⁻⁶ cm/s |

General Protocol for Transport Assays

General Considerations

CacoReady is designed for conducting permeability *in vitro* assays of established and investigational compounds in order to predict their absorption and interaction with membrane-associated proteins (transporters: MDR1 (Pgp) and BCRP).

Recommended Reference Compounds

The compounds listed below (also referenced in the "Solutions" section) are recommended for testing as a reference for low- and high-permeability compounds and for substrates of the MDR1 (Pgp) transport protein.

- Recommended reporter for Low Permeability Substrates: Atenolol (SIGMA Cat#A7655)
- Recommended reporter for High Permeability Substrates: Metoprolol (SIGMA Cat#M5391)
- Recommended reporter for MDR1 (Pgp) Substrates: Digoxin (SIGMA Cat# 04599)
- Recommended reporter for MDR1 (Pgp) Inhibitors: Verapamil (SIGMA Cat# V4629)
- Recommended reporter for BCRP Substrates: Prazosin (SIGMA Cat# P7791)
- Recommended reporter for BCRP Inhibitors: Ko143 (SIGMA Cat# K2144)

Sample Plate Layout

The CacoReady 24-well format allows evaluating the permeability of 1 compound in triplicate in the A-B/B-A directions following the recommended plate layout shown below.

| | A-B | | | B-A | | | A-B | | | B-A | | |
|---|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| A | Atenolol_R1 | Atenolol_R2 | Atenolol_R3 | Atenolol_R1 | Atenolol_R2 | Atenolol_R3 | Comp 2_R1 | Comp 2_R2 | Comp 2_R3 | Comp 2_R1 | Comp 2_R2 | Comp 2_R3 |
| B | Metoprolol_R1 | Metoprolol_R2 | Metoprolol_R3 | Metoprolol_R1 | Metoprolol_R2 | Metoprolol_R3 | Comp 2/Inh_R1 | Comp 2/Inh_R2 | Comp 2/Inh_R3 | Comp 2/Inh_R1 | Comp 2/Inh_R2 | Comp 2/Inh_R3 |
| C | Digoxin_R1 | Digoxin_R2 | Digoxin_R3 | Digoxin_R1 | Digoxin_R2 | Digoxin_R3 | Comp 3_R1 | Comp 3_R2 | Comp 3_R3 | Comp 3_R1 | Comp 3_R2 | Comp 3_R3 |
| D | Dig/Verap_R1 | Dig/Verap_R2 | Dig/Verap_R3 | Dig/Verap_R1 | Dig/Verap_R2 | Dig/Verap_R3 | Comp 3/Inh_R1 | Comp 3/Inh_R2 | Comp 3/Inh_R3 | Comp 3/Inh_R1 | Comp 3/Inh_R2 | Comp 3/Inh_R3 |
| E | Prazosin_R1 | Prazosin_R2 | Prazosin_R3 | Prazosin_R1 | Prazosin_R2 | Prazosin_R3 | Comp 4_R1 | Comp 4_R2 | Comp 4_R3 | Comp 4_R1 | Comp 4_R2 | Comp 4_R3 |
| F | Praz/Ko143_R1 | Praz/Ko143_R2 | Praz/Ko143_R3 | Praz/Ko143_R1 | Praz/Ko143_R2 | Praz/Ko143_R3 | Comp 4/Inh_R1 | Comp 4/Inh_R2 | Comp 4/Inh_R3 | Comp 4/Inh_R1 | Comp 4/Inh_R2 | Comp 4/Inh_R3 |
| G | Comp 1_R1 | Comp 1_R2 | Comp 1_R3 | Comp 1_R1 | Comp 1_R2 | Comp 1_R3 | Comp 5_R1 | Comp 5_R2 | Comp 5_R3 | Comp 5_R1 | Comp 5_R2 | Comp 5_R3 |
| H | Comp 1/Inh_R1 | Comp 1/Inh_R2 | Comp 1/Inh_R3 | Comp 1/Inh_R1 | Comp 1/Inh_R2 | Comp 1/Inh_R3 | Comp 5/Inh_R1 | Comp 5/Inh_R2 | Comp 5/Inh_R3 | Comp 5/Inh_R1 | Comp 5/Inh_R2 | Comp 5/Inh_R3 |

R = replicate

Figure 3. Recommended sample plate layout to investigate drug intestinal absorption and potential drug-transporter interactions.

At (atenolol), Met (metoprolol), Dig (digoxina), Praz (prazosin), Comp (compound), Inh (inhibitor).

- Initial concentration suggested for unknowns: 10 μ M
- Replicates: 3
- Time points: 0 and 2 h
- Volumes: *Apical compartment*: 75 μ L
Basal compartment: 250 μ L

NOTE: The procedure should be undertaken in biosafety level II containment standards to ensure sterile conditions. Assay transport buffer solution should be pre-warmed to 37 °C to avoid temperature stress. Do not use LY and tested compounds concomitantly in the same well. LY may interfere with certain substances, resulting in false data.

Protocol

The general procedure for permeability assays in the A-B/B-A directions is represented in Annex I.

Apical-to-Basal Studies

Test compounds are applied to the apical side of the cell monolayer (upper compartment of the insert), and the apical-to-basal (A-B) transport through the cell barrier is evaluated by sample recovery and test compound detection in the basal (lower) compartment over a defined incubation period. A-B permeability of test compounds is determined as the coefficient of apparent permeability (P_{app}) in cm/s.

Preparation

1. Prepare stock solutions of reference and tested compounds in transport buffer. In case of poorly water-soluble compounds, DMSO may be used as a solvent. If so, it is recommended to keep the percentage of DMSO in the assay buffer below 1 %.
2. Prepare working solutions of unknowns and reference compounds in transport buffer. Substrates and inhibitors are mixed simultaneously in the working solution when both compounds are concomitantly assayed.
3. Fill a reagent reservoir with pre-warmed (37 °C) transport buffer.
4. Take the reservoir plate into the laminar flow hood.
5. Remove one CacoReady plate from the cell incubator and place it beside the reservoir plate. Both plates should be oriented the same way.

Washing Steps

6. Open the CacoReady plate and the reservoir plate, and leave the lids upwards next to the plates.
7. Carefully lift the 96 apical inserts of the CacoReady plate and transfer them to the reservoir plate.
8. Using the 96-well manifold, aspirate the cell culture medium from the lower compartments of the CacoReady plate.
9. Using a multichannel pipette, fill, column by column, each of the 96 wells of the lower compartments of the CacoReady plate with 250 μ L of pre-warmed (37 °C) transport buffer.
10. Using the 96-well manifold, aspirate the cell culture medium of the apical inserts of the CacoReady plate. Place the manifold perpendicular to the cell monolayer and close to the insert wall to avoid disturbing the cell monolayer.
11. Using a multichannel pipette, fill, column by column, each of the 96 apical inserts of the upper compartment of the CacoReady plate with 75 μ L of pre-warmed (37 °C) transport buffer.
12. Carefully return the 24 apical inserts onto the wells of the basal compartment of the CacoReady plate (original position).
13. Incubate the plate for 1 minute at room temperature inside the laminar flow hood.
14. Repeat steps 6 to 12 twice. The first time, incubate the plate as performed in step 13. The second time, incubate the plate for 30 minutes in the cell incubator (37 °C, 5 % CO₂).

NOTE: Use low-medium suction power to avoid disrupting the cell monolayer.

Transport Assay

15. Take the plate from the incubator, return it to the laminar flow hood and place it next to the reservoir plate. Both plates should be oriented in the same way.
16. Carefully lift the 24 apical inserts of the CacoReady plate and transfer them to the reservoir plate.

17. Using the 96-well manifold, aspirate the transport buffer from the lower compartment of the CacoReady plate.
18. Using a multichannel pipette, fill, column by column, each of the 96 wells of the lower compartments of the CacoReady plate with 250 μ L of pre-warmed (37 °C) transport buffer.
19. Using the 96-well manifold, aspirate the transport buffer of the apical inserts of the CacoReady plate. Place the manifold perpendicular to the cell monolayer and close to the insert wall to avoid disturbing the cell monolayer.
20. Add 100 μ L of working solutions (see sample layout in Figure 3 for details) to the 96 apical inserts of the CacoReady plate. Immediately after (0 hours), recover 25 μ L (t₀) and keep them at -20 °C until further analysis is performed.
21. Carefully return the 96 apical inserts onto the wells of the basal compartment of the CacoReady plate (original position) and leave the plate in the cell incubator (37 °C, 5 % CO₂) for 2 hours. Shorter or longer periods of incubation may be required for very high or low permeability compounds.

NOTE: Use low-medium suction power to avoid disrupting the cell monolayer.

Sample Collection

22. Take the plate from the incubator, return it to the laminar flow hood and place it next to the reservoir plate. Transfer the apical inserts onto the reservoir plate.
23. Recover 25 μ L from the apical inserts (t_{2h} apical) and the lower compartments (t_{2h} basal), and keep them at -20 °C until further analysis is performed.
24. Analyze all samples using mass spectrometry according to your analytical procedures for tested and reference compounds.
25. Calculate the compound apparent permeability (P_{app}) coefficient as indicated in the following section ("Evaluation of Compound Permeability").

Basal-to-Apical Studies

Test compounds are applied to the basal side of the cell monolayer (lower compartment of the insert), and the basal-to-apical (B-A) transport through the cell barrier is evaluated by sample recovery and test compound detection in the apical (upper) compartment over a defined incubation period. B-A permeability of test compounds is determined as the coefficient of apparent permeability (P_{app}) in cm/s.

All steps are identical to those described for the apical-to-basal studies, except for the volumes added in steps 18 and 20:

Step 18. Using a multichannel pipette, fill, column by column, each of the 96 wells of the upper compartment of the CacoReady plate with 75 μ L of pre-warmed (37 °C) transport buffer.

Step 20. Add 275 μ L of working solutions (see sample layout in Figure 3 for details) to the basal compartments of the CacoReady plate. Immediately after (0 hours), recover 25 μ L (t₀) and keep them at -20 °C until further analysis is performed.

NOTE: At the end of the transport assay (A-B/B-A directions) perform the post-assay quality control as indicated in the section "Quality control of the barrier system".

Evaluation of Compound Permeability

Apparent Permeability Coefficient (P_{app})

The transport efficiency of test substances and reference compounds is evaluated in each sample through P_{app} calculation, which is defined as follows:

$$P_{app} = \frac{dQ}{dt} \times \frac{1}{A \times C_0}$$

where P_{app} represents the coefficient of apparent permeability (in cm/s), which corresponds to the proportion of test compound that crosses the barrier at each time point (dQ/dt in nmol/s), divided by the product of the crossed area (A in cm^2) by the initial concentration of test compound (C_0 in nmol/ml) applied to the apical (A-B) or basal (B-A) compartments.

Considerations for calculations:

- When plotting Q versus time, consider the amount of material lost in previous stages
- A single time point can only be used in the linear range. Otherwise, the P_{app} value will be an underestimation of the real value. Sampling compounds with unknown behavior at a single time point is not recommended.

Efflux Ratio (ER)

The efflux ratio is a general measure of the involvement of active processes in compound permeability. This value results from dividing the compound P_{app} in the B-A direction by the P_{app} in the A-B direction.

$$ER = \frac{P_{app \text{ B-A}}}{P_{app \text{ A-B}}}$$

Mass Balance

Material balance calculation for each compound is determined as follows:

$$\text{Mass Balance (\%)} = \left[\frac{((C_{ap@time(i)} \times V_{ap}) + (C_{bs@time(i)} \times V_{bs}))}{C_{init@time0} \times V} \right] \times 100$$

Where

- $C_{ap@time(i)}$ and $C_{bs@time(i)}$ correspond to test compound concentrations in pmols/mL at time (i) in the apical and basal compartments, respectively.
- V_{ap} and V_{bs} are apical and basal volumes in mL.
- $C_{init@time0}$ is the initial concentration of the test compound in pmols/mL at t_0 .
- V is the volume of either the apical compartment (A-B direction) or the basal compartment (B-A direction).

Data for Reference Compounds

Normal values and ranges for reference substances (according to FDA guidelines¹ and MedTech Barcelona's internal data) are detailed below:

- TEER values $> 500 \Omega \times \text{cm}^2$ and LY paracellular flux values $\leq 0.7 \%$ are strong indicators of cell barrier integrity.
- Substrates of membrane protein transporters must have an efflux ratio greater than 2.
- In the presence of transporter inhibitors, the substrate's efflux ratio must decrease significantly ($> 50 \%$).
- Material balance (mass balance) range must be between 80 % - 120 %.

| CacoReady 96 | | | | | | |
|-------------------|---------------|--------------------|---------------------------------|-------------------------------------|------------------|-------|
| Substrate | Inhibitor | Permeability range | Concentration (μM) | Papp ($\times 10^6 \text{ cm/s}$) | | ER |
| | | | | A-B | B-A | |
| Atenolol | --- | Low | 10 | 0.29 ± 0.03 | 0.10 ± 0.01 | 0.33 |
| Nadolol | --- | | 10 | 0.34 ± 0.02 | 0.11 ± 0.01 | 0.33 |
| Metformin | --- | | 10 | 0.91 ± 0.65 | 0.07 ± 0.04 | 0.08 |
| Pindolol | --- | Medium | 10 | 5.93 ± 0.92 | 9.59 ± 0.79 | 1.62 |
| Metoprolol | --- | High | 10 | 30.07 ± 4.58 | 13.81 ± 2.14 | 0.46 |
| Caffeine | --- | | 10 | 27.46 ± 2.20 | 14.90 ± 1.33 | 0.54 |
| Digoxin | --- | | 10 | 0.77 ± 0.04 | 9.12 ± 1.26 | 11.88 |
| Digoxin | Cyclosporin A | Pgp substrate | 10:10 | 0.76 ± 0.05 | 3.92 ± 0.76 | 5.16 |
| Talinolol | --- | | 10 | 0.14 ± 0.09 | 2.26 ± 0.51 | 15.82 |
| Talinolol | Verapamil | | 10:50 | 6.23 ± 2.54 | 0.91 ± 0.68 | 0.15 |
| Estrone-3-sulfate | --- | BCRP substrate | 10 | 0.51 ± 0.19 | 9.70 ± 1.71 | 19.17 |
| Prazosin | --- | | 10 | 2.14 ± 0.16 | 17.18 ± 1.18 | 8.01 |

Table 2. Apparent permeability (Papp) coefficient values and efflux ratio of reference compounds across CacoReady.

References

¹ Food and Drug Administration (FDA) (2020). In Vitro Drug Interaction Studies — Cytochrome P₄₅₀ Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry. U.S. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER). <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/vitro-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions>